Biotech BD & Licensing Events

Evolus, Inc. entered into an exclusive License, Supply and Distribution Agreement with IBSA Institut Biochimique SA for Profhilo®, an injectable hyaluronic acid product for skin-quality applications in the U.S. aesthetics and dermatological fields. Evolus will be responsible for U.S. development, clinical, and regulatory activities to support FDA approval and will purchase the product from IBSA under a transfer-price model post-approval. No upfront or milestone payments are required from Evolus.

Pfizer is reaffirming its fiscal year 2026 financial guidance, including projected revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00. This reaffirmation follows the disclosure of a Chief Financial Officer transition announcement and aligns with previously issued guidance.

Organon & Co. is proceeding with its merger with Sun Pharmaceutical Holdings USA, Inc. A lawsuit was filed alleging incomplete disclosures in the definitive proxy statement, seeking to enjoin the stockholder vote. To avoid delays and litigation risks, Organon voluntarily supplemented the proxy statement, denying the claims' merit. The Board continues to evaluate strategic alternatives, including Sun Pharma's proposal, while considering execution risks associated with other options.

Jasper Therapeutics, Inc. acquired Kira Pharmaceuticals through a merger, issuing common and convertible preferred stock to Kira's shareholders. Concurrently, a private placement occurred, resulting in pre-transaction Jasper equityholders holding approximately 6.68% of the fully-diluted common stock, former Kira equityholders 49.86%, and new investors 43.46%. Additionally, pre-merger Jasper shareholders received Contingent Value Rights, entitling them to a pro rata portion of $30.0 million if briquilimab receives a Priority Review Voucher by December 31, 2028.

Praxis Precision Medicines, Inc. entered into a research collaboration and license agreement with Remagine Labs, Inc. to develop an iontophoretic transdermal patch for ulixacaltamide, targeting essential tremor. This collaboration aims to leverage Remagine's proprietary transdermal drug delivery system to broaden ulixacaltamide's patient reach and strengthen its competitive positioning, complementing Praxis's existing oral program. Praxis also made an equity investment in Remagine.